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Delivery of sTRAIL variants by MSCs in
combination with cytotoxic drug treatment leads to
p53-independent enhanced antitumor effects
R Yu1,2, L Deedigan1,2, SM Albarenque1, A Mohr1,3 and RM Zwacka*,1,3
Mesenchymal stem cells (MSCs) are able to infiltrate tumor tissues and thereby effectively deliver gene therapeutic payloads.
Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL),
which is a potent inducer of apoptosis in tumor cells, and tested these MSCs, termed MSC.sTRAIL, in combination with
conventional chemotherapeutic drug treatment in colon cancer models. When we pretreated human colorectal cancer HCT116
cells with low doses of 5-fluorouracil (5-FU) and added MSC.sTRAIL, we found significantly increased apoptosis as compared
with single-agent treatment. Moreover, HCT116 xenografts, which were cotreated with 5-FU and systemically delivered
MSC.sTRAIL, went into remission. Noteworthy, this effect was protein 53 (p53) independent and was mediated by TRAIL-receptor
2 (TRAIL-R2) upregulation, demonstrating the applicability of this approach in p53-defective tumors. Consequently, when we
generated MSCs that secreted TRAIL-R2-specific variants of soluble TRAIL (sTRAIL), we found that such engineered MSCs,
labeled MSC.sTRAILDR5, had enhanced antitumor activity in combination with 5-FU when compared with MSC.sTRAIL. In
contrast, TRAIL-resistant pancreatic carcinoma PancTu1 cells responded better to MSC.sTRAILDR4 when the antiapoptotic
protein XIAP (X-linked inhibitor of apoptosis protein) was silenced concomitantly. Taken together, our results demonstrate that
TRAIL-receptor selective variants can potentially enhance the therapeutic efficacy of MSC-delivered TRAIL as part of
individualized and tumor-specific combination treatments.
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The tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) is a potent and specific inducer of apoptosis in
tumor cells and can also act as a powerful cancer-preventive
agent.1,2 It can bind to four membrane-bound receptors and
one soluble receptor (TRAIL-R1, TRAIL-R2, TRAIL-R3,
TRAIL-R4 and osteoprotegerin also known as DR4, DR5,
decoy receptor 1 (DcR1), decoy receptor 2 (DcR2) and OPG,
respectively). Both TRAIL receptors 1 and 2 (TRAIL-R1 and
TRAIL-R2) contain a conserved cytoplasmic region termed
the death domain (DD) that is required for TRAIL-induced
apoptosis.3 Upon binding of TRAIL, a protein complex is
formed known as death-inducing signaling complex (DISC)
consisting of TRAIL-R1 and/or TRAIL-R2, the adaptor protein
Fas-associated death domain (FADD) and procaspase-8.4
Activation of caspase-8 at the DISC and subsequent
activation of effector caspases leads to apoptosis.5 In
contrast, TRAIL receptors 3 and 4 (TRAIL-R3 and TRAIL-
R4) and the soluble receptor OPG have inhibitory functions,
because they lack the intracellular DDs, and are therefore
regarded as decoy receptors.1 Therefore, one potential way of
improving the therapeutic efficacy of TRAIL is to generate
agents that act in a TRAIL-R-specific way, preferring one of
the two death receptors and potentially avoiding the decoy
receptors. To this end, agonistic antibodies directed against
one of the two apoptosis-inducing TRAIL-Rs have been
developed and tested in various experimental systems as well
as in the clinic.6–9 In addition, engineered variants of the
TRAIL protein, containing specific amino-acid changes lead-
ing to specific targeting of TRAIL-R1 or TRAIL-R2 have been
developed and have shown enhanced antitumor properties
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in vitro and in vivo.10–13 However, in clinical trials with
recombinant TRAIL (rTRAIL) protein and agonistic antibodies
to TRAIL-R2, only moderate therapeutic activities have been
found.14 A possible explanation for the problems with
recombinant protein and antibodies is limited bioavailability
owing to short half-life of the protein or restricted accessibility
of large antibodies to tumor tissue, respectively.15 Cell and
gene therapy approaches provide a potential strategy to
overcome such limitations and several cellular gene delivery
vectors utilizing TRAIL as its therapeutic payload have shown
efficacy in experimental tumor models.16–20 In particular,
mesenchymal stem cells (MSCs) have been used in this
context, as they are known to readily infiltrate tumor
tissues.21,22 However, limitations to this approach have been
highlighted in a recent study that demonstrated the require-
ment for substantial intratumoral presence of MSCs to afford
growth inhibition in a colorectal carcinoma model.23 There-
fore, it is essential to derive as much therapeutic effect from
the tumor-infiltrating MSCs as possible, because in a clinical
setting the number of MSCs that can be safely injected and
consequently the number of tumor-infiltrating MSCs might be
limited. Thus, the use of sTRAIL as compared with full-length
membrane-bound TRAIL19 and integration of TRAIL-R-
specific variants10–13 are valuable approaches to augment
the antineoplastic effects of the MSC-based delivery system.
A further barrier for TRAIL therapies is that a substantial
proportion of tumors are relatively resistant to the effects of
TRAIL.24 To this end, we could show that a sensitization
approach with the commonly used anticancer compound 5-
fluorouracil (5-FU) in conjunction with systemically adminis-
tered MSC.sTRAIL worked in vitro and in vivo. The effect was
mediated by protein 53 (p53)-independent increases in the
expression of TRAIL-R2, and consequently MSCs secreting a
TRAIL-R2-specific sTRAIL variant (MSC.sTRAILDR5) gave
rise to significantly higher apoptosis than MSC.sTRAIL (wild-
type sTRAIL) or MSC.sTRAILDR4 (TRAIL-R1-specific variant)
in 5-FU-pretreated HCT116 cells. In a second sensitization
approach, we targeted the antiapoptotic protein XIAP (X-
linked inhibitor of apoptosis protein) by RNA interference
(RNAi) in TRAIL-resistant pancreatic carcinoma cells and
could show that MSC.sTRAILDR4 exerted significantly
increased apoptosis-inducing activity as compared with
MSC.sTRAIL or MSC.sTRAILDR5. Hence, MSC-mediated
delivery of optimized sTRAIL variants to tumors combined
with conventional chemotherapy or inhibition of apoptosis
resistance factors such as XIAP could become a novel,
patient-tailored treatment strategy for various oncological
diseases.
Results
Combined treatment of 5-FU and TRAIL leads to
synergistic apoptosis induction. Because TRAIL as a
stand-alone strategy is unlikely to be efficacious in all cancer
types and cases owing to apoptosis resistance of tumor cells,
we set out to test optimized TRAIL-based approaches
utilizing combination treatments with the cytotoxic drug 5-
FU and MSC-mediated delivery of sTRAIL. First, we
determined the minimal concentrations of rTRAIL and 5-FU
that could be used in a combination treatment of colorectal
cancer cells. HCT116 cells were treated with 5-FU at
concentrations of 10, 50, 100, 200 and 400mM (Figure 1a)
and rTRAIL at concentrations of 0.25, 0.5, 1, 2 and 5 ng/ml
(Figure 1a). The results show increasing apoptosis levels
with rising concentrations of the respective apoptosis-
inducing agent. For our combination treatment experiment,
we chose concentrations of the two agents that gave rise to
relatively low specific apoptosis levels and thus pretreated
HCT116 cells with 10 mM 5-FU for 24 h followed by 1 ng/ml
rTRAIL for an additional 24 h before we measured cell death.
This combined treatment resulted in 37±0.6% apoptosis as
compared with 2.6±0.4% and 10.5±0.4% apoptosis,
respectively, for the single treatments (Figure 1a). Apoptosis
could be completely blocked by the pan-caspase inhibitor
zVAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoro-
methylketone), demonstrating that the detected cell death
was a caspase-dependent apoptotic process (Figure 1a).
A significant problem for clinical use of TRAIL is effective
delivery and sufficient bioavailability in tumor lesions of the
recombinant protein or agonistic TRAIL-R antibodies.15
In order to overcome this problem, we and others have
exploited the tumor-infiltrating properties of MSCs to deliver
sTRAIL.17–19 Here, we have constructed an adenoviral (Ad)
vector (Ad.sTRAIL) that contained the ectodomain of TRAIL
(aa114–aa289) fused to the secretory signal peptide from the
human Fibrillin-1 gene (hFIB), a Furin cleavage site (Furin CS)
and an Isoleucine zipper (ILZ) domain under the control of
the cytomegalovirus (CMV) promoter/enhancer element
(Figure 1b).25 The vector Ad.sTRAIL was used to transduce
MSCs, which had been characterized by their capacity for
adipogenic, osteogenic and chondrogenic differentiation
(Figure 1b) as well as by fluorescence-activated cell sorting
(FACS) analyses with an array of surface marker antibodies.
The results show that our murine MSCs (mMSCs) are
CD29þ , Sca-1þ , CD44þ , CD11b , CD19 , CD117 ,
CD45 and Ter 119 , demonstrating their purity and
ruling out a contamination with fibroblasts and hematopoietic
cells (Figure 1b). The resulting modified MSCs that expressed
and secreted sTRAIL were termed MSC.sTRAIL
(Supplementary Figure S1a–d). Mixing of MSC.sTRAIL with
HCT116 cells that had been pretreated with 10 mM 5-FU for
24 h gave rise to significant increased apoptosis levels in the
double-treated cells (5-FU/MSC.sTRAIL) as compared with
the single treatments or a 5-FU/MSC.DsRed control combina-
tion (Figure 1c). As we obtained the same significant
sensitization effect when we transferred the medium super-
natant from MSC.sTRAIL 48 h after transduction with Ad.
sTRAIL onto 5-FU-pretreated HCT116, we could conclude
that the effect was indeed exerted by secreted sTRAIL and not
via direct MSC–cancer cell interactions (Figure 1c).
Combined treatment of 5-FU and TRAIL is efficacious
and safe in vivo. Based on our in vitro findings we
examined the utility of 5-FU in combination with MSC.sTRAIL
in HCT116 xenografts. First, we tested the duration of
transgene expression in adenovirally transduced MSCs
in vitro to inform our in vivo regimen (Supplementary Figure
S2) and assessed the effect of 5-FU on MSCs and their
potential to secrete sTRAIL as well as to induce apoptosis in
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the presence of 5-FU. The results revealed that a second
injection of MSC.sTRAIL 10 days after the first administration
might be helpful, as transgene expression in MSCs dropped
substantially between day 8 and day 12 after transduction
and that MSCs are 5-FU resistant and sTRAIL secretion is
not affected by 5-FU (Supplementary Figure S3a–d). Thus,
MSCs can be used as cellular delivery vehicle in the context
of an experimental 5-FU/MSC.sTRAIL treatment.
Next, we established tumors in immune-deficient nu/nu
mice. These mice were then intraperitoneally injected with
150mg/kg 5-FU before 1 105 MSC.sTRAIL were systemi-
cally administered via the tail vein. After 10 days, the mice
were treated with a second dose of 1 105 MSC.sTRAIL. As
controls, we tested tumors that were treated with MSC.DsRed
together with 5-FU as well as MSC.sTRAIL or MSC.DsRed
alone. Although the tumors in the control group, treated with
MSC.DsRed, grew almost exponentially, xenografts either
treated with 5-FU/MSC.DsRed or MSC.sTRAIL showed
marked growth reduction. Most strikingly, tumors treated with
the combination of 5-FU and MSC.sTRAIL went into remis-
sion (Figure 2a). When we analyzed the tumors histologically
by hematoxylin and eosin (H&E) staining to examine general
tissue morphology, and by Masson’s trichrome staining to
visualize the connective tissue (collagen fibers), we found
MSC.DsRed and 5-FU/MSC.DsRed sections showing a
nonencapsulated tumor with cancer cell infiltration of the
surrounding muscle tissue in the H&E analysis (Figure 2b).
The same tumors stained with the Masson’s trichrome
method showed that 5-FU/MSC.DsRed had some fiber
development inside the tumor mass (Figure 2b). H&E- and
Masson’s trichrome-stained MSC.sTRAIL tumor samples
showed fiber formation surrounding the tumor that still looked
Figure 1 Cancer cells can be sensitized to the effects of MSC.sTRAIL by 5-FU. (a) Apoptosis was measured after exposure of HCT116 cells to increasing doses of 5-FU.
Cells were treated for 48 h with the respective doses of 5-FU (left). HCT116 cells were treated with rTRAIL with increasing concentrations and apoptosis measured 24 h later
(center). Apoptosis measurements after treatment with 10 mM 5-FU for 48 h, treatment with rTRAIL at 1 ng/ml for 24 h or pretreatment with 10 mM 5-FU for 24 h followed by
1 ng/ml rTRAIL for an additional 24 h. Addition of zVAD directly to the HCT116 cells before 5-FU pretreatment completely inhibited apoptosis of the combined treatment (5-FU
followed by rTRAIL). Carrier (dimethylsulfoxide (DMSO)) treatment had no effect (right). Data represent averages±S.E.M. (n¼ 3, Po0.001). (b) Schematic drawing of the
sTRAIL construct depicts the signal peptide sequence from the human Fibrillin-1 gene (hFIB) that was ligated to the Furin cleavage site (Furin CS), an Isoleucine zipper (ILZ)
stretch and the sTRAIL (ectodomain) part (aa114–aa289). The expression was driven by a conventional CMV promoter/enhancer element (left). Murine MSCs and their
differentiation potential was analyzed by a von-Kossa osteogenesis assay, an Oil Red O staining for adipogenic differentiation and Toluidine Blue staining for chondrogenesis
(center). FACS analyses of mouse MSCs for surface expression of CD117, CD11b, CD19, CD45, TER-119, CD44, Sca-1 and CD29. The three respective isotype controls are
shown in gray (right). (c) Mixing of 10mM 5-FU-pretreated HCT116 cells with MSC.sTRAIL in a ratio of 10 : 1 showed significantly increased apoptosis as compared with 5-FU/
MSC.DsRed or MSC.sTRAIL treatments. Additional controls are 5-FU and MSC.DsRed treatments (left). Data represent averages±S.E.M. (n¼ 3, Po0.001). Transfer of
medium supernatants (SNs) from MSC.sTRAIL onto 5-FU-pretreated HCT116 cells also gave rise to significantly higher apoptosis levels compared with SNs from
MSC.sTRAIL that were applied to non-5-FU-treated HCT116 cells or in 5-FU/MSC.DsRed samples. Additional controls are supernatants from MSC.DsRed or 5-FU-only
treated HCT116 cells (right). Data represent averages±S.E.M. (n¼ 3, Po0.001)
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proliferating but limited by a capsule (Figure 2b). In contrast,
5-FU/MSC.sTRAIL clearly showed a lot of cellular debris
mixed with collagen fibers replacing the proliferating cells that
were present in the other samples (Figure 2b). In addition,
nuclear proliferating cell nuclear antigen (PCNA) protein
expression, which is observed during DNA synthesis and
generally represents cellular proliferating activity, was
detected immunohistochemically (Figure 2b). In the
MSC.DsRed and 5-FU/MSC.DsRed groups, PCNA levels
were higher compared with MSC.sTRAIL tumor samples and
were almost absent in sections from the 5-FU/MSC.sTRAIL
group (Figure 2b). Hence, whereas 5-FU andMSC.sTRAIL as
single-agent regimens possess significant but limited antic-
ancer activities, the combination of both gave rise to tumor
remission.
Next, we tested the safety of combined 5-FU/TRAIL
treatments on primary murine and human cells. To this end,
we incubated murine and human MSCs with 10 mM 5-FU for
24 h followed by rTRAIL (10 ng/ml) for an additional 24 h
period. When wemeasured apoptosis in these cells, we found
that they were resistant to the single treatments as well as to
the combination of 5-FU and rTRAIL (Figure 2c). Furthermore,
we examined the livers of mice that had received 5-FU
injections followed by MSC.sTRAIL and could not detect any
signs of tissue injury or cell death in these tissue samples
(Figure 2d), indicating that the present novel therapeutic
approach is safe.
The molecular mechanism of TRAIL sensitization by
5-FU. In order to further improve TRAIL-based combination
treatments, a better understanding of the underlying mole-
cular mechanism(s) of the observed sensitization is impor-
tant. First, we analyzed caspase-8 activation, which is one of
the initial molecular events in the TRAIL-triggered apoptosis
pathway, in 5-FU/TRAIL-treated HCT116 cells. Our results
demonstrate that caspase-8 activation is markedly increased
in cells exposed to the combined treatment as compared with
cells treated with either 5-FU or rTRAIL alone (Figure 3a). In
order to show that the 5-FU sensitization effect is indeed
transduced through the canonical caspase-8-initiated
Figure 2 Treatment with 5-FU and MSC.sTRAIL lead to tumor remission in vivo. (a) Immune-deficient mice were injected with 5 106 HCT116 cells. After 10 days
(¼ day 0 of treatment regimen) 150mg/kg 5-FU was injected intraperitoneally and subsequently 1 105 MSC.DsRed (blue line; n¼ 4) or MSC.sTRAIL (red line; n¼ 6) was
intravenously administered. Animals in two additional control groups received MSC.DsRed (black line; n¼ 4) or MSC.sTRAIL (green line; n¼ 4) alone without 5-FU. The
animals were injected with engineered MSCs on day 0 and again on day 10, as indicated by arrows. The tumor growth was followed over 33 days and is depicted in the graph
(P¼ 0.003, P¼ 0.02 and P¼ 0.03). (b) H&E staining (upper panel) to examine general tumor tissue morphology and Masson’s trichrome staining (center panel) to visualize
the connective tissue (collagen in connective tissue is stained blue and cytoplasm appears in pink) on microsections fromMSC.DsRed-, 5-FU/MSC.DsRed-, MSC.sTRAIL- and
5-FU/MSC.sTRAIL-treated HCT116 tumor-burdened animals. Immunohistochemical detection of nuclear PCNA protein expression (brown color) on microsections of
MSC.DsRed-, 5-FU/MSC.DsRed-, MSC.sTRAIL- and 5-FU/MSC.sTRAIL-treated HCT116 tumors (lower panel). Scale bars, 200mm. (c) Apoptosis was measured after
exposure of murine and human MSCs to 10 mM 5-FU for 48 h (black bars), treatment with rTRAIL at 10 ng/ml for 24 h (red bars) or pretreatment with 10 mM 5-FU for 24 h
followed by 10 ng/ml rTRAIL for an additional 24 h (white bars). HCT116 cells treated with the same concentration of 5-FU, but with 1 ng/ml rTRAIL, served as positive control.
Data represent averages±S.E.M. (n¼ 3, Po0.001). (d) H&E staining of liver sections from mice treated with MSC.DsRed, 5-FU/MSC.DsRed, MSC.sTRAIL and 5-FU/
MSC.sTRAIL, respectively. Scale bars, 500mm. High-power images of the boxed-in areas of the respective tissue sections are shown in the lower panel of images.
Scale bars, 200mm
sTRAIL variants and 5-FU lead to tumor remission
R Yu et al
4
Cell Death and Disease
apoptosis pathway or whether additional, independent
mechanisms and factors are required, we generated stable
caspase-8 knockdowns in HCT116 cells, termed HCT.shc8
(Figure 3a). These cells were treated with the standard
5-FU/TRAIL regimen and apoptosis was measured showing
that in HCT.shc8 cells apoptosis was completely inhibited,
Figure 3 5-FU-induced, p53-independent TRAIL-R2 upregulation is responsible for the sensitization effect. (a) Caspase-8 western blot of HCT116 cells that were either
left untreated, treated with 5-FU (10 mM; 48 h), rTRAIL (1 ng/ml; 24 h) or 5-FU (10 mM; 24 h) followed by rTRAIL (1 ng/ml; additional 24 h). Pro-caspase bands are marked by
an (*), whereas cleavage products indicative of activation are labeled by arrows. The CuZn superoxide dismutase (CuZnSOD) blot is a loading control (left). Caspase-8
western blot of protein lysates from a control knockdown clone of HCT116 cells (HCT.shctrl) and a caspase-8 knockdown clone (HCT.shc8). The CuZnSOD blot served as
loading control (center). HCT.shctrl (black bars) and HCT.shc8 (red bars) were pretreated with 5-FU (10 mM) for 24 h and then treated with rTRAIL (1 ng/ml) for 24 h before
apoptosis was measured. Controls include HCT.shctrl and HCT.shc8 cells treated only with 5-FU or rTRAIL (right). Data represent averages±S.E.M. (n¼ 3, Po0.001). (b)
A cFlip western blot of protein lysates from untreated and 5-FU-stimulated (10 mM; 48 h) HCT116 cells. The CuZnSOD immunoblot is the loading control (left). FACS analyses
for TRAIL-R1 and TRAIL-R2 demonstrated that only TRAIL-R2 is substantially upregulated following treatment with 5-FU for 24 h (black bars) and 48 h (green bars) (right).
(c) Western blots for TRAIL-R1 (top panel) and TRAIL-R2 (lower panel) of protein lysates from HCT.shctrl clones as well as from HCT116 derivatives with RNAi-mediated
silenced TRAIL-R1 (HCT.shDR4) and TRAIL-R2 (HCT.shDR5), respectively. CuZnSOD western blots served as loading controls (left). HCT.shDR4 (red bars) and HCT.shctrl
cells (black bars) were pretreated with 5-FU (10 mM) for 24 h followed by rTRAIL (1 ng/ml) for an additional 24 h and apoptosis was measured. Controls include HCT.shctrl and
HCT.shDR4 cells treated with 5-FU or rTRAIL alone (center). Data represent averages±S.E.M. (n¼ 3, Po0.001). HCT.shDR5 (red bars) and HCT.shctrl (black bars) were
pretreated with 5-FU for 24 h and then stimulated with rTRAIL (1 ng/ml) for an additional 24 h and apoptosis was measured. Additional controls were HCT.shctrl and
HCT.shDR5 cells treated with 5-FU or rTRAIL alone (right). Data represent averages±S.E.M. (n¼ 3, Po0.001). (d) FACS analyses of fold upregulation of surface
expression of TRAIL-R1 (left) and TRAIL-R2 (center left) in HCT116 and HCTp53 / cells at 24 h (black bars), 48 h (green bars) and 72 h (blue bars) after 5-FU treatment
(10mM) in relation to untreated cells. Apoptosis measurements in HCTp53 / cells after pretreatment with 10 mM 5-FU for 24 h, followed by treatment with rTRAIL at 1 ng/
ml for an additional 24 h (black bars) and pretreatment with 10mM 5-FU for 48 h followed by 1 ng/ml rTRAIL for an additional 24 h (green bars) (center right). Data represent
averages±S.E.M. (n¼ 3, Po0.001). HT-29 cells were treated with 10 mM 5-FU for 72 h, treated with rTRAIL at 0.5 ng/ml for 24 h and pretreated with 10 mM 5-FU for 48 h
followed by 0.5 ng/ml rTRAIL for an additional 24 h, respectively (right). Data represent averages±S.E.M. (n¼ 3, Po0.001)
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demonstrating that caspase-8 was the sole initiator caspase
and that the sensitization effect of 5-FU was not mediated by
mechanisms outside of the normal extrinsic apoptosis path-
way (Figure 3a). Thus, molecularly, the observed 5-FU-
mediated sensitization is located at the level of caspase-8
activation or upstream of it. Although these results show that
caspase-8 is required for 5-FU/TRAIL-triggered apoptosis,
we could not detect any indications that 5-FU gave rise to
elevated levels of caspase-8, thereby making a role as
molecular driver of the observed 5-FU sensitization effect
unlikely. Instead, we turned to the antiapoptotic protein cFlip
(cellular FLICE-like inhibitory protein), as others have
implicated 5-FU-triggered downregulation of cFlip in the
sensitization effect.26 However, although decreased levels of
cFlip protein after 5-FU stimulation could indeed explain
enhanced caspase-8 activation, we were unable to detect
any decreases in cFlip levels (Figure 3b). Next, we examined
changes in the surface levels of TRAIL-R1 and TRAIL-R2 by
FACS after 5-FU treatment, because increased TRAIL-R
expression could lead to higher caspase-8 activation and
apoptosis in response to TRAIL, and as in particular TRAIL-
R2 has been shown to be upregulated by 5-FU via a
mechanism that is believed to be p53 dependent.27 Following
5-FU treatment, we detected a substantial rise in TRAIL-R2
expression but almost no effect on the TRAIL-R1 levels
(Figure 3b). To test whether the increased TRAIL-R2 levels
could prime the cells for increased TRAIL responsiveness,
we generated stable TRAIL-R2 and as controls TRAIL-R1
knockdown clones in HCT116 cells, labeled HCT.shDR5 and
HCT.shDR4, respectively (Figure 3c). When the HCT.shDR4
cells were treated with 5-FU followed by rTRAIL, we
observed significantly elevated levels of cell death as
compared with control cells (Figure 3c). In contrast, in
HCT.shDR5 cells, 5-FU/TRAIL-induced apoptosis was sig-
nificantly reduced (Figure 3c). These results strongly point to
the upregulation of TRAIL-R2 as the molecular driver of the
5-FU-induced sensitization effect. In contrast, TRAIL-R1 not
only had no role in the observed sensitization, but silencing of
this receptor gave rise to a significant increase in 5-FU/
TRAIL-induced apoptosis, most likely owing to the fact that
TRAIL-R2 molecules can form more readily active homo-
trimers and consequently induce a higher level of apoptosis
with no or very little interfering TRAIL-R1 present in the
membrane. Following these findings, we wondered whether
the upregulation of TRAIL-R2 and consequent sensitization
to TRAIL is p53 dependent. When we subjected HCT116 and
HCTp53 / cells to the standard 5-FU pretreatment and
measured TRAIL-R2 and TRAIL-R1 levels, we found TRAIL-
R2 protein expression to be upregulated in HCTp53 /
cells 24 h later as compared with HCT116 cells (Figure 3d),
whereas TRAIL-R1 levels were almost unchanged in both
cell types. Consequently, 5-FU-mediated TRAIL-induced
apoptosis sensitization reached the same levels in
HCTp53 / cells as in HCT116 cells, although in a time-
delayed fashion (Figure 3d). To test that 5-FU sensitization is
not restricted to HCT116 and HCTp53 / cells, we
additionally analyzed HT-29 human colorectal cancer cells,
which harbor a R273H p53 mutation, and found that they
could also be sensitized to the apoptosis-inducing effects of
TRAIL by pretreatment with 5-FU (Figure 3d). These results
demonstrate that the 5-FU-mediated sensitization strategy is
independent of p53, but based on p53 status, modified
regimens have to be used with respect to the optimal time
point of the TRAIL or MSC.sTRAIL administration. Further-
more, given the importance of TRAIL-R2, we hypothesized
that the use of TRAIL-R-specific variants that specifically
induce apoptosis via TRAIL-R2 might increase the efficacy of
the MSC.sTRAIL system further.
Soluble TRAIL variants sTRAILDR5 and sTRAILDR4 are
specific for TRAIL-R2 and TRAIL-R1, respectively. In
addition to the wild-type TRAIL construct containing the
consensus TRAIL cDNA sequence, we integrated two
TRAIL-R-specific variants, one selective for TRAIL-R1
(DR4) and one for TRAIL-R2 (DR5) into our expression
construct. These variants were designed by using the
automatic design algorithm FOLD-X28 and have been
previously described and tested as recombinant proteins
(without the ILZ).13 One amino-acid sequence change was
introduced into the TRAIL segment, namely an aspartate to
histidine change at position 269 (D269H) to generate the
DR5-specific variant (sTRAILDR5), whereas the DR4-specific
variant (sTRAILDR4) was generated by a serine to argenine
change at position 159 (S159R) (Figure 4a). The resulting
expression constructs were transfected into 293 cells, tested
by Western blot (Figure 4b) and the level of sTRAIL in the
supernatant measured by ELISA (Figure 4b). The results
demonstrate that the different sTRAIL variants were
expressed and secreted at comparable levels. In order to
confirm the TRAIL receptor specificity of the sTRAILDR5 and
sTRAILDR4 variants, we used the HCT.shDR5 and
HCT.shDR4 cells. When these cells were treated with
supernatants from 293 cells secreting sTRAILDR5 or
sTRAILDR4, we found that HCT.shDR5 cells showed mark-
edly reduced apoptosis in response to sTRAILDR5 in
comparison with HCT116 cells, whereas the cell death levels
with sTRAILDR4 and sTRAIL were normal (Figure 4c). In
contrast, HCT.shDR4 exhibited significantly decreased
apoptosis with sTRAILDR4, but elevated levels with
sTRAILDR5 (Figure 4c). These findings indicate that the
sTRAIL variants indeed induce apoptosis via one of the two
receptors in a specific manner and that they hold promise to
improve the effectiveness of our MSC.sTRAIL system.
The variants sTRAILDR5 and sTRAILDR4 induce increased
apoptosis in different cancer cells. To further test the
activities of the TRAIL-R-specific variants, we transfected
293 cells with the three constructs expressing sTRAIL,
sTRAILDR5 and sTRAILDR4, respectively, harvested the
supernatant media after 48 h, adjusted the sTRAIL concen-
tration to 2 ng/ml sTRAIL and transferred the supernatants
onto an array of cancer cells. We found cancer cell-specific
differences with regard to their propensity to undergo
apoptosis via TRAIL-R2 or TRAIL-R1. On one hand, human
ovarian cancer A2780 cells, human pancreatic BxPC-3 cells,
human colorectal cancer cells HCT116 and Colo205 cells
showed increased apoptosis when treated with supernatants
from sTRAILDR5-producing 293 cells (Figure 5a), and on the
other hand, human pancreatic carcinoma Colo357 cells and
human cervical cancer Hela cells exhibited elevated cell
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death rates with sTRAILDR4 (Figure 5b). The differences in
specific apoptosis between the sTRAILDR5 and sTRAILDR4
variants were 38.5 percentage points for A2780 cells, 17.8
percentage points for BxPC-3 cells and 11.5 percentage
points and 21.4 percentage points for HCT116 cells and
Colo205 cells, respectively. For the cells that predominantly
used the TRAIL-R1 pathway, the differences were 7.4
percentage points and 8 percentage points for Colo357 and
Hela cells, respectively, in favor of sTRAILDR4. Although
these analyses focused on differences between sTRAILDR5
and sTRAILDR4, they did not fully reveal the advantages of
the respective TRAIL variants over wild-type sTRAIL. We
hypothesized that decreasing sTRAIL concentrations would
better unearth such differences. Therefore, we treated
Colo205 cells with a lower dose of sTRAIL and its variants
(0.5 ng/ml). We found that at this concentration sTRAILDR5
induced apoptosis levels that were equal to those obtained
with 2 ng/ml, that is, 495%, whereas apoptosis induction
with sTRAIL and sTRAILDR4 dropped to levels measured with
control supernatants (Figure 5c). These results demonstrate
that sTRAIL variants can have a markedly augmented
therapeutic potential as compared with wild-type sTRAIL.
Thus, we sought to combine TRAIL-R-specific variants with
the MSC-based delivery system.
The sTRAIL variants expressed and secreted from MSCs
induce apoptosis in cancer cells. Having established
functionality and specificity of the sTRAIL variants, we
generated adenoviral vectors with expression cassettes
containing the TRAIL-R-specific sTRAIL forms. These
adenoviral vectors, termed Ad.sTRAILDR4 and
Ad.sTRAILDR5, respectively, were, together with Ad.sTRAIL,
used to transduce murine MSCs. The resulting MSCs
expressing the sTRAIL variants were labeled
MSC.sTRAILDR4 and MSC.sTRAILDR5, respectively. The
levels of sTRAIL were visualized by western blot and found
to be equal for all three sTRAIL forms (Figure 6a). Mixing
MSC.sTRAILDR5 with Colo205 cells at cellular ratios of 1 : 5,
1 : 10 and 1 : 20 led to significantly more apoptosis than with
MSC.sTRAIL or MSC.sTRAILDR4, demonstrating the higher
susceptibility of Colo205 cells to undergo apoptosis via a
TRAIL-R2-mediated pathway (Figure 6b). When we assayed
Figure 4 Receptor-specific sTRAIL variants are expressed and act specifically. (a) Schematic drawing of the sTRAIL, sTRAILDR5 (TRAIL-R2-specific) and sTRAILDR4
(TRAIL-R1-specific) constructs. The TRAILR-specific variants were generated by site-directed mutagenesis inserting a D269H and an S159R amino-acid exchange in the
sTRAIL ectodomain, respectively. The expression was driven by a conventional CMV promoter/enhancer element in all three constructs. (b) These sTRAIL expression
constructs were transiently transfected into 293 cells. After 24 h, whole-cell lysates were analyzed by western blotting for TRAIL, revealing similar expression levels for all three
constructs. CuZn superoxide dismutase (CuZnSOD) was used as a loading control (left). Results of ELISA analyses for TRAIL demonstrating similar secretion of sTRAIL
(black), sTRAILDR5 (green) and sTRAILDR4 (red) into the supernatant of transfected 293 cells. Results for cells transfected with an enhanced green fluorescent protein (EGFP)
control plasmid are shown in gray (right). (c) Supernatants from 293 cells transfected with either an EGFP control expression plasmid (gray), sTRAIL (black), sTRAILDR5
(green) or sTRAILDR4 (red) were normalized to 2 ng/ml TRAIL (the EGFP control was diluted 1 : 2 in fresh medium) and then applied to HCT116, HCT.shDR5 and HCT.shDR4
cells, respectively, before apoptosis was measured 24 h later. Data represent averages±S.E.M. (n¼ 3, P¼ 0.008, P¼ 0.01, P¼ 0.004)
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apoptosis at the molecular level, we found that
MSC.sTRAILDR5 more profoundly induced caspase-8 activa-
tion than MSC.sTRAIL and MSC.sTRAILDR4 (Figure 6b).
These results were supported by caspase-3 western blots
that showed full caspase-3 activation in MSC.sTRAILDR5-
treated Colo205 cells, significantly less in MSC.sTRAIL-
stimulated cells and no caspase-3 activation in the
MSC.sTRAILDR4 sample (Figure 6b). In contrast, in Hela
cells, addition of MSC.sTRAILDR4 gave rise to markedly
higher apoptosis levels compared with MSC.sTRAIL and
MSC.sTRAILDR5 (Figure 6c). Analyzing caspase-8 activation
by western blot revealed that in accordance with the
apoptosis results, MSC.sTRAILDR4 gave rise to the strongest
caspase-8 activation (Figure 6c). In addition, caspase-3
immunoblots showed that only MSC.sTRAILDR4 caused full
activation as evident by the appearance of the active
fragments (Figure 6c). Taken together, these results show
that MSCs can be utilized to secrete sTRAIL variants that in
turn can more effectively induce apoptosis in different cancer
cells.
Figure 5 Apoptosis analyses of a panel of cancer cells reveal divergent responses to sTRAILDR5 and sTRAILDR4. (a) Supernatants from 293 cells that were transfected
with enhanced green fluorescent protein (EGFP; gray), sTRAILDR5 (green) and sTRAILDR4 (red) constructs were diluted down to 2 ng/ml TRAIL and then transferred onto
A2780, BxPC-3, HCT116 and Colo205 cells. Subsequent apoptosis measurements (24 h) showed that these tumor cells were significantly more responsive to sTRAILDR5 than
to sTRAILDR4. Data represent averages±S.E.M. (n¼ 3, Po0.001, P¼ 0.001, P¼ 0.008, P¼ 0.02). (b) Colo357 and Hela cells were incubated with the same EGFP (gray),
sTRAILDR5 (green) and sTRAILDR4 (red) 293 cell supernatants (normalized to 2 ng/ml of TRAIL) for 24 h before apoptosis was measured revealing that these tumor cells
underwent apoptosis preferentially via TRAIL-R1. Data represent averages±S.E.M. (n¼ 3, P¼ 0.001, P¼ 0.04). (c) Colo205 cells were treated with 293 cell supernatants
normalized to a lower TRAIL concentration of 0.5 ng/ml. The apoptosis results for EGFP (gray), sTRAIL (black), sTRAILDR5 (green) and sTRAILDR4 (red) demonstrate that
sTRAILDR5 has superior activity not only over sTRAILDR4 but also over sTRAIL at this low concentration. Data represent averages±S.E.M. (n¼ 3, Po0.001, Po0.001)
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Combination treatments enhance the effects of MSC.
sTRAILDR5 and MSC.sTRAILDR4 in colon and pancreatic
cancer cells. After having demonstrated the utility of 5-FU
sensitization to MSC.sTRAIL-induced apoptosis in vivo on
one side as well as the potential of TRAIL-R-specific variants
on the other, we sought to combine these two approaches.
In particular, as we had found that 5-FU sensitization to
TRAIL was mediated by TRAIL-R2 and its upregulation,
we hypothesized that TRAIL-R2-specific variants could
afford superior cancer cell killing effects in this context. We
pretreated HCT116 cells with 5-FU for 24 h, after which
MSC.sTRAIL, MSC.sTRAILDR5 and MSC.sTRAILDR4 were
added for another 24 h, before apoptosis was measured.
We found that pretreatment with 5-FU led to signifi-
cantly increased apoptosis levels after treatment with
MSC.sTRAILDR5 compared with MSC.sTRAIL and MSC.
sTRAILDR4 (Figure 7a). To study the specificity of
MSC.sTRAILDR4 and MSC.sTRAILDR5 in combination with
5-FU, we mixed them with HCT116, HCT.shDR4 and
HCT.shDR5 cells that had been pretreated with 5-FU. Our
Figure 6 MSC.sTRAILDR5 and MSC.sTRAILDR4 induce increased apoptosis in different cancer cells. (a) Equal TRAIL expression in MSC.sTRAIL, MSC.sTRAILDR5 and
MSC.sTRAILDR4 was demonstrated by western blot. (b) MSC.DsRed (gray), MSC.sTRAIL (black), MSC.sTRAILDR5 (green) and MSC.sTRAILDR4 (red) were mixed with
Colo205 cells at different ratios (1 : 5, 1 : 10 and 1 : 20) for 24 h. Then, cells were harvested and apoptosis was measured (left). Data represent averages±S.E.M. (n¼ 3,
Po0.001). Caspase-8 (right, upper panel) and caspase-3 (right, lower panel) activation of the highest mix ratio (1 : 5) was determined by western blotting analysis. Pro-
caspase bands are marked by an (*), whereas cleavage products indicative of activation are indicated by arrows. The CuZn superoxide dismutase (CuZnSOD) blot served as
loading control. (c) MSC.DsRed (gray), MSC.sTRAIL (black), MSC.sTRAILDR5 (green) and MSC.sTRAILDR4 (red) were mixed with Hela cells at different ratios (1 : 5, 1 : 10 and
1 : 20) for 24 h before apoptosis was measured (left). Data represent averages±S.E.M. (n¼ 3, P¼ 0.002, P¼ 0.002). Caspase-8 (right, upper panel) and caspase-3 (right,
lower panel) western blots show the different caspase-8 and caspase-3 activation levels in an experiment, in which MSCs and Hela cells were mixed 1 : 5. Pro-caspase-8 and
 3 are marked by an (*) and proteolytic cleavage fragments are indicated by arrows. The CuZnSOD blot is the loading control
sTRAIL variants and 5-FU lead to tumor remission
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results show that in pretreated HCT.shDR4 and HCT116
cells, MSC.sTRAILDR5 showed higher apoptosis levels
whereas in HCT.shDR5 the 5-FU sensitization effect was
blocked, demonstrating that it was mediated by TRAIL-R2
(Figure 7a). Noteworthy, MSC.sTRAILDR4 exerted augmen-
ted apoptosis-inducing activity on HCT.shDR5, as no TRAIL-
R2 could impede the formation of TRAIL-R1 homo-
trimers, resulting in more efficient apoptosis induction by
the TRAIL-R1-specific variant (Figure 7a). Accordingly,
MSC.sTRAILDR5 gave rise to more cell death in 5-FU-
pretreated HCT.shDR4 cells (Figure 7a). Thus,
MSC.sTRAILDR5 is the preferred system in combination with
5-FU in this case. However, in addition to Hela and Colo357
cells (Figure 5b), we and others have shown that in
pancreatic cancer cells TRAIL-induced apoptosis is prefer-
entially mediated via TRAIL-R1 and is profoundly enhanced
by XIAP inhibition.29,30 Therefore, to also test utility of TRAIL-
R1-specific variants in conjunction with an alternative
sensitization approach to 5-FU, namely XIAP inhibition, we
generated stable XIAP knockdown clones of the TRAIL-
resistant pancreatic PancTu1 cancer cell line. These clones
were named PancTu1.shXIAP and were shown to harbor no
detectable XIAP levels by western blot (Figure 7b). When we
treated PancTu1.shXIAP cells with MSC.sTRAIL,
MSC.sTRAILDR4 and MSC.sTRAILDR5, we could measure
apoptosis in all three cases, but MSC.sTRAILDR4 gave rise to
significantly higher cell death rates than MSC.sTRAIL and
MSC.sTRAILDR5 (Figure 7b). These findings are in line with
our previous findings29,30 and underline that pancreatic
cancer cells undergo apoptosis preferentially via TRAIL-R1.
In summary, TRAIL-R-specific variants offer a substantial
improvement over normal TRAIL as they can better target
TRAIL-resistant cancer cells and act more specifically and
effectively in combined treatment approaches.
Discussion
MSCs are pluripotent adult stem cells that are normally
derived from bone marrow and have the potential to
differentiate in vitro along numerous mesenchymal
lineages.31 As MSCs have been shown to infiltrate tumor
tissues,21,22 they have been employed in various experimen-
tal cancer therapeutic approaches, including those that make
use of their proposed intrinsic anticancer properties or as a
delivery vehicle for therapeutic anticancer transgenes.32 To
this end, we and others have shown that MSCs expressing
TRAIL led to growth retardation or remission of human lung,
glioblastoma, breast and pancreatic carcinoma xenografts,
respectively, as well as inhibition of metastasis forma-
tion.17,19,33–35 In order to increase the effects of MSC-
mediated TRAIL delivery further, we analyzed pretreatment
of cancer cells with 5-FU in combination with MSC.sTRAIL.
5-FU is a pyrimidine analog that is used in the treatment
of cancer.36 It belongs to the family of drugs called
Figure 7 Cancer cells can be sensitized to treatment with MSC.sTRAIL variants by silencing of XIAP and 5-FU pretreatment. (a) HCT116 cells were pretreated with 10mM
5-FU for 24 h before they were mixed with MSC.DsRed (gray), MSC.sTRAIL (black), MSC.sTRAILDR5 (green) and MSC.sTRAILDR4 (red) at different ratios (1 : 5, 1 : 10 and
1 : 20) for another 24 h before apoptosis was measured. The apoptosis rate with MSC.sTRAILDR5 was significantly increased after pretreatment with 5-FU (left). Data represent
averages±S.E.M. (n¼ 3, P¼ 0.007, P¼ 0.05, P¼ 0.01). In order to demonstrate specificity, HCT.shDR5 (center) and HCT.shDR4 (right) were also mixed with MSC.DsRed
(gray), MSC.sTRAIL (black), MSC.sTRAILDR5 (green) and MSC.sTRAILDR4 (red) at different ratios (1 : 5, 1 : 10 and 1 : 20) and apoptosis was measured 24 h later. Data
represent averages±S.E.M. (n¼ 3, P¼ 0.006, Po0.001; n¼ 3, Po0.001, Po0.001, Po0.001). (b) XIAP western blot from protein lysates of PancTu1.shctrl and
PancTu1.shXIAP cells. The CuZn superoxide dismutase (CuZnSOD) blot served as loading control (left). Mixing of MSC.DsRed (gray), MSC.sTRAIL (black), MSC.sTRAILDR5
(green) and MSC.sTRAILDR4 (red) at different ratios (1 : 5, 1 : 10 and 1 : 20) with PancTu1.shXIAP cells for 48 h. Subsequent apoptosis measurements showed that in
PancTu1.shXIAP cells MSC.sTRAILDR4 had the best effect (right). Data represent averages±S.E.M. (n¼ 3, Po0.001, P¼ 0.02, Po0.001)
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antimetabolites and works through irreversible inhibition of
thymidylate synthase. 5-FU has been shown to sensitize to
TRAIL-induced apoptosis via various mechanisms including
upregulation of TRAIL-R expression and/or downregulation of
the anti-apoptotic protein cFlip.26 As its principal use is in
colorectal cancer, in which it has been the established form of
chemotherapy for decades, we tested 5-FU pretreatment
followed byMSC.sTRAIL in HCT116 human colorectal cancer
cells. We found pretreating with low doses of 5-FU greatly
enhanced apoptosis when the HCT116 cells were subse-
quently mixed with MSC.sTRAIL. Furthermore, when we
established HCT116 xenografts in mice, pretreated them with
5-FU followed by systemic administration of MSC.sTRAIL, we
saw complete remission of the tumors as compared with
partial responses in the cohort treated with MSC.sTRAIL
alone. HCT116 cells are p53 proficient, whereas a substantial
fraction of tumors are p53 mutated and/or dysfunctional.
Therefore, in order to assess whether this sensitization
strategy would also be applicable in p53-defective tumor
cells, we analyzed p53-mutated and p53-negative colon
cancer cells, HT-29 and HCTp53 / cells, respectively.
We were able to sensitize both cell lines to the effects of
TRAIL by 5-FU pretreatment, demonstrating that the
approach also has utility in p53-deficient tumors. Subse-
quently, we sought to elucidate the underlying molecular
mechanism of the 5-FU sensitization in order to be able to
design further improvements into the MSC.sTRAIL system.
We found that this sensitization effect was caused by 5-FU-
induced, p53-independent upregulation of TRAIL-R2, as
RNAi-mediated silencing of TRAIL-R2, but not of TRAIL-R1,
resulted in inhibition of 5-FU/TRAIL-induced apoptosis.
Hence, we set out to develop MSCs that express and secrete
TRAIL variants that specifically target TRAIL-R2 to achieve
greater apoptosis induction in 5-FU-treated tumor cells. First,
we cloned the cDNAs coding for TRAIL variants that acted
through TRAIL-R1, as control, and TRAIL-R2, respectively,
into adenoviral expression constructs, which were used to
transduce MSCs, giving rise to MSC.sTRAILDR4 and
MSC.sTRAILDR5. Indeed, when we mixed 5-FU-stimulated
HCT116 cells with MSC.sTRAIL, MSC.sTRAILDR4 or
MSC.sTRAILDR5, we measured the highest apoptosis levels
in the cancer cells that were treated with MSC.sTRAILDR5.
Taken together, a targeted therapy with MSC.sTRAILDR5 in
combination with 5-FU appears to be a viable treatment
approach even for p53-deficient tumors.
However, many tumors are resistant to TRAIL-induced
apoptosis owing to mechanisms downstream of the receptor
and the DISC, which means that 5-FU-mediated TRAIL-R
upregulation (alone) would not be a viable sensitization
strategy. To this end, we and others have documented the
importance of the antiapoptotic protein XIAP, known to be
frequently upregulated in cancers, and its utility as a
therapeutic target.37,38 Pancreatic cancers in particular are
known to be aggressive and resistant to apoptosis at least in
part owing to high XIAP levels.39 In the present study, we
generated stable XIAP knockdown clones by RNAi in the
pancreatic cancer cell line PancTu1 and treated them with our
array of MSC.sTRAIL variants. We found that in contrast to
their parental counterparts, XIAP-silenced cells were sensi-
tive to the effects of MSC-produced sTRAIL,19 and also found
that in this context PancTu1 responded better to TRAIL-R1-
specific sTRAIL, as we have reported previously in a similar
approach using agonistic TRAIL-R1-specific antibodies.30 As
several XIAP/IAP inhibitors are currently in clinical tests, the
silencing of XIAP or its functions is a potential approach and
can be achieved either pharmacologically or through
improved RNAi tools40–42 in a potential, future clinical setting.
Furthermore, although MSC.sTRAILDR5 were the optimal
system in particular for 5-FU-primed colorectal cancer cells,
the effects on other tumor cells that were not treated with 5-FU
were more divergent. In Colo205, HCT116, BxPc-3 and
A2780 cells, sTRAILDR5 showed the best effects, whereas
sTRAILDR4 induced more apoptosis in Hela, Colo357 and
PancTu1.shXIAP cells, indicating that in certain cases TRAIL-
R1-specific variants are more efficacious. Therefore, it would
be valuable to be able to predict the responsiveness of cancer
cells to the different TRAIL variants. To this end, we have
previously reported that the expression levels of the different
TRAIL-Rs can be a predicting factor for TRAIL responsive-
ness.43 In line with those results, on Colo205 cells, which
trigger apoptosis preferentially via TRAIL-R2, TRAIL-R1 is
undetectable. Thus, although the predictive potential of
TRAIL-R expression is limited, it can still serve as a first-line
test aiding in deciding which TRAIL variant to use. Overall, our
results demonstrate that TRAIL-R-specific TRAIL variants are
significantly more efficacious than wild-type TRAIL, in
particular in combination with 5-FU.
Materials and Methods
Reagents and cell culture. All chemicals and reagents unless otherwise
stated, were purchased from Sigma (St Louis, MO, USA). Media were purchased
from Invitrogen (Carlsbad, CA, USA) unless otherwise stated. Recombinant TRAIL
was from R&D Systems (Minneapolis, MN, USA) and zVAD from Santa Cruz
(Santa Cruz, CA, USA). Antibodies and cells are described in the Supplementary
Materials and Methods section. 293 cells were transiently transfected using the
calcium phosphate transfection method, which is described in more detail in the
Supplementary Materials and Methods section.
Apoptosis assay. Apoptosis was measured according to Nicoletti et al.44 and
has been described previously.45 Please see Supplementary Materials and
Methods for detail.
Generation of adenoviral vectors and transduction of MSCs.
Recombinant E1/E3-deleted adenoviral vectors (Ad.sTRAIL, Ad.sTRAILDR4,
Ad.sTRAILDR5 and control Ad.DsRed) were generated using the ViraPower
adenoviral expression system (Invitrogen) as described earlier.34 Transduction of
MSCs was carried out as described earlier.34 TRAIL variants, sTRAILDR5 (D269H)
and sTRAILDR4 (S159R), were generated using the Quick-Change site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) and confirmed by DNA
sequencing. Please see Supplementary Materials and Methods for detail.
Isolation, expansion and differentiation assays of MSCs. MSCs
from 4- to 6-week old FVB/N (FVB/n mouse strain) mice were prepared based on
the method of Peister et al.46 The cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM)–low glucose with 100 U/ml penicillin, 100mg/ml streptomycin and
15% fetal bovine serum (FBS). Differentiation assays for MSCs were carried out
as described previously.21 The murine MSCs (mMSCs) are generally referred to
as MSCs throughout the text.
Cell surface staining and FACS analyses. The surface expression of
TRAIL-Rs was measured by incubating cells with R-phycoerythrin (PE)-conjugated
mouse anti-human TRAIL-R1 and mouse anti-human TRAIL-R2 as described
previously.34 The same procedure was used to stain for CD11b, CD19, CD117,
CD45, TER-119, CD29, Sca-1 and CD44.19
sTRAIL variants and 5-FU lead to tumor remission
R Yu et al
11
Cell Death and Disease
Mixing of MSCs with tumor cells. Tumor cells were plated in six-well
plates at 105 cells per well and left overnight to adhere. Then, cells were
pretreated with 10mM 5-FU or left untreated. Adenovirus-transduced MSCs (48 h)
were then added 24 h later at different ratios in fresh medium. Another 24 h later,
cells were collected for apoptosis assays. The supernatants of adenovirally
transduced MSCs were diluted (1 : 5) and also added onto HCT116 cells.
Animal studies. Ten-week-old female CD1 nu/nu (Crl:CD1-Foxn1nu) mice
(Charles River, Wilmington, MA, USA) were injected with 5 106 HCT116 cells in
200ml phosphate-buffered saline (PBS). After 10 days, and when tumors were
palpable, the animals were intraperitoneally injected with 5-FU (150mg/kg) and
intravenously with 1 105 MSCs that had been transduced with the respective
adenoviral vectors 24 h earlier. The injections were repeated 10 days later. The
growth of the tumors was then followed over 33 days. The tumor volume was
calculated using three different diameters and the formula: p/6 (d1 d2 d3).
The animal studies were performed according to national laws and covered by
license from the Irish government.
Histological analyses. Please see Supplementary Materials and Methods
for detail.
Western blot. Western blots were principally carried out as described
previously.47 Please see Supplementary Materials and Methods for detail.
TRAIL enzyme-linked immunosorbent assay (ELISA). To examine
secreted sTRAIL, the culture supernatants of transfected 293 cells and transduced
MSCs were cleared by centrifugation at 2000 g for 20min. The supernatants
were diluted and a commercial TRAIL ELISA kit (R&D Systems) was used
following the manufacturer’s instructions. Please see Supplementary Materials and
Methods for detail.
RNAi knockdown constructs and stable cell line generation.
Small hairpin (sh) RNA motifs were expressed inside pU6.ENTR and pBlock-iT
plasmids (Invitrogen). Please see Supplementary Materials and Methods for
sequence information and further details.
Statistical analysis. If not stated, three independent experiments were
performed. Experimental values are expressed as mean value±S.E.M. For
significance analyses, analysis of variance (ANOVA) between groups was used
and *Pr0.05 was considered significant, **Pr0.01 as highly significant and
***Pr0.001 as extremely significant.
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